Comparative Pharmacology
Head-to-head clinical analysis: LOMANATE versus LONOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOMANATE versus LONOX.
LOMANATE vs LONOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LOMANATE is a combination of diphenoxylate (a peripheral opioid receptor agonist that slows GI motility) and atropine (an anticholinergic that discourages abuse).
Loperamide is an opioid receptor agonist that acts on mu-opioid receptors in the myenteric plexus of the large intestine, inhibiting peristalsis and prolonging transit time. It also reduces colonic water and electrolyte secretion, enhancing fluid and electrolyte absorption. Loperamide has low systemic bioavailability due to extensive first-pass metabolism and is not significantly absorbed into the central nervous system due to P-glycoprotein efflux transport.
100 mg orally twice daily
1-2 mg orally every 6 hours as needed for diarrhea; maximum 8 mg per day.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours in adults with normal renal function; prolonged to 40-60 hours in severe renal impairment (CrCl < 30 mL/min), requiring dose adjustment.
Terminal half-life 12-15 hours; prolonged (up to 30 h) in elderly and renal impairment.
Primarily renal (80% as unchanged drug and metabolites); biliary/fecal (15%); 5% eliminated via other routes.
Primarily renal (60-70% as unchanged drug and active metabolite); biliary/fecal ~20%.
Category C
Category C
Antidiarrheal
Antidiarrheal